Guidelines for anti-emetic therapy

Acute emesis

A. A. Fauser, M. Fellhauer, M. Hoffmann, H. Link, G. Schlimok, Richard J. Gralla

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Anti-emetic therapy has become integral to the management of patients with cancer. Goals related to complete emesis control include providing treatment that reduces hospitalisation and time in the ambulatory setting, care that is convenient for the patient and therapy that enhances patients' quality of life. A panel of clinical, health economic and basic scientists with expertise in various oncology disciplines reviewed published literature to develop evidence-based consensus guidelines for the prevention and treatment of chemotherapy-induced emesis. Currently, serotonin receptor antagonists and corticosteroids are the two categories of anti-emetics that are most effective, have the fewest side-effects and are convenient to use. These agents are recommended in combination for highly emetogenic chemotherapy regimens and as single agents or in combination for moderately to highly emetogenic chemotherapy. When possible, these agents may be given orally in single doses; current evidence does not support dose escalation for either category of anti-emetics. In special situations, such as the use of high-dose chemotherapy combination regimens, the most emetogenic component of the regimen should dictate the choice of anti-emetic. Appropriate anti- emetic use described in these guidelines represents both good medical practice and a sensible economic approach to care.

Original languageEnglish (US)
Pages (from-to)361-370
Number of pages10
JournalEuropean Journal of Cancer
Volume35
Issue number3
DOIs
StatePublished - Mar 1999
Externally publishedYes

Fingerprint

Antiemetics
Vomiting
Guidelines
Drug Therapy
Economics
Therapeutics
Serotonin Antagonists
Ambulatory Care
Combination Drug Therapy
Adrenal Cortex Hormones
Hospitalization
Quality of Life
Health
Neoplasms

Keywords

  • 5- hydroxytryptamine (5-HT) antagonist
  • Anti-emetic therapy
  • Cancer
  • Chemotherapy
  • Corticosteroid
  • Emesis
  • Serotonin antagonist
  • Supportive care

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Fauser, A. A., Fellhauer, M., Hoffmann, M., Link, H., Schlimok, G., & Gralla, R. J. (1999). Guidelines for anti-emetic therapy: Acute emesis. European Journal of Cancer, 35(3), 361-370. https://doi.org/10.1016/S0959-8049(98)00417-1

Guidelines for anti-emetic therapy : Acute emesis. / Fauser, A. A.; Fellhauer, M.; Hoffmann, M.; Link, H.; Schlimok, G.; Gralla, Richard J.

In: European Journal of Cancer, Vol. 35, No. 3, 03.1999, p. 361-370.

Research output: Contribution to journalArticle

Fauser, AA, Fellhauer, M, Hoffmann, M, Link, H, Schlimok, G & Gralla, RJ 1999, 'Guidelines for anti-emetic therapy: Acute emesis', European Journal of Cancer, vol. 35, no. 3, pp. 361-370. https://doi.org/10.1016/S0959-8049(98)00417-1
Fauser, A. A. ; Fellhauer, M. ; Hoffmann, M. ; Link, H. ; Schlimok, G. ; Gralla, Richard J. / Guidelines for anti-emetic therapy : Acute emesis. In: European Journal of Cancer. 1999 ; Vol. 35, No. 3. pp. 361-370.
@article{e72c82399bd54cd09fa600f149cb3067,
title = "Guidelines for anti-emetic therapy: Acute emesis",
abstract = "Anti-emetic therapy has become integral to the management of patients with cancer. Goals related to complete emesis control include providing treatment that reduces hospitalisation and time in the ambulatory setting, care that is convenient for the patient and therapy that enhances patients' quality of life. A panel of clinical, health economic and basic scientists with expertise in various oncology disciplines reviewed published literature to develop evidence-based consensus guidelines for the prevention and treatment of chemotherapy-induced emesis. Currently, serotonin receptor antagonists and corticosteroids are the two categories of anti-emetics that are most effective, have the fewest side-effects and are convenient to use. These agents are recommended in combination for highly emetogenic chemotherapy regimens and as single agents or in combination for moderately to highly emetogenic chemotherapy. When possible, these agents may be given orally in single doses; current evidence does not support dose escalation for either category of anti-emetics. In special situations, such as the use of high-dose chemotherapy combination regimens, the most emetogenic component of the regimen should dictate the choice of anti-emetic. Appropriate anti- emetic use described in these guidelines represents both good medical practice and a sensible economic approach to care.",
keywords = "5- hydroxytryptamine (5-HT) antagonist, Anti-emetic therapy, Cancer, Chemotherapy, Corticosteroid, Emesis, Serotonin antagonist, Supportive care",
author = "Fauser, {A. A.} and M. Fellhauer and M. Hoffmann and H. Link and G. Schlimok and Gralla, {Richard J.}",
year = "1999",
month = "3",
doi = "10.1016/S0959-8049(98)00417-1",
language = "English (US)",
volume = "35",
pages = "361--370",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Guidelines for anti-emetic therapy

T2 - Acute emesis

AU - Fauser, A. A.

AU - Fellhauer, M.

AU - Hoffmann, M.

AU - Link, H.

AU - Schlimok, G.

AU - Gralla, Richard J.

PY - 1999/3

Y1 - 1999/3

N2 - Anti-emetic therapy has become integral to the management of patients with cancer. Goals related to complete emesis control include providing treatment that reduces hospitalisation and time in the ambulatory setting, care that is convenient for the patient and therapy that enhances patients' quality of life. A panel of clinical, health economic and basic scientists with expertise in various oncology disciplines reviewed published literature to develop evidence-based consensus guidelines for the prevention and treatment of chemotherapy-induced emesis. Currently, serotonin receptor antagonists and corticosteroids are the two categories of anti-emetics that are most effective, have the fewest side-effects and are convenient to use. These agents are recommended in combination for highly emetogenic chemotherapy regimens and as single agents or in combination for moderately to highly emetogenic chemotherapy. When possible, these agents may be given orally in single doses; current evidence does not support dose escalation for either category of anti-emetics. In special situations, such as the use of high-dose chemotherapy combination regimens, the most emetogenic component of the regimen should dictate the choice of anti-emetic. Appropriate anti- emetic use described in these guidelines represents both good medical practice and a sensible economic approach to care.

AB - Anti-emetic therapy has become integral to the management of patients with cancer. Goals related to complete emesis control include providing treatment that reduces hospitalisation and time in the ambulatory setting, care that is convenient for the patient and therapy that enhances patients' quality of life. A panel of clinical, health economic and basic scientists with expertise in various oncology disciplines reviewed published literature to develop evidence-based consensus guidelines for the prevention and treatment of chemotherapy-induced emesis. Currently, serotonin receptor antagonists and corticosteroids are the two categories of anti-emetics that are most effective, have the fewest side-effects and are convenient to use. These agents are recommended in combination for highly emetogenic chemotherapy regimens and as single agents or in combination for moderately to highly emetogenic chemotherapy. When possible, these agents may be given orally in single doses; current evidence does not support dose escalation for either category of anti-emetics. In special situations, such as the use of high-dose chemotherapy combination regimens, the most emetogenic component of the regimen should dictate the choice of anti-emetic. Appropriate anti- emetic use described in these guidelines represents both good medical practice and a sensible economic approach to care.

KW - 5- hydroxytryptamine (5-HT) antagonist

KW - Anti-emetic therapy

KW - Cancer

KW - Chemotherapy

KW - Corticosteroid

KW - Emesis

KW - Serotonin antagonist

KW - Supportive care

UR - http://www.scopus.com/inward/record.url?scp=0033105567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033105567&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(98)00417-1

DO - 10.1016/S0959-8049(98)00417-1

M3 - Article

VL - 35

SP - 361

EP - 370

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 3

ER -